Nonmyeloablative conditioning after transplantation with high-dose cyclophosphamide. The figure summarizes the results of 3 similar clinical trials of nonmyeloablative conditioning and transplantation of partially HLA-mismatched bone marrow at Johns Hopkins, Fred Hutchinson Cancer Research Center, or BMT Group of Georgia and Hahnemann University Hospital. Reprinted from Munchel et al with permission.⁹⁷  (A) Actuarial curves of overall survival (OS) and EFS in 210 patients undergoing nonmyeloablative HSCT with posttransplantation cyclophosphamide. (B) OS in patients with ALL, AML, or myelodysplastic syndrome (MDS) or myeloproliferative disorder (MPD).